Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification

[1] Garralda E(2014)Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment Clin Cancer Res 20 2476-2484

[2] Paz K(2011)Global cancer statistics CA Cancer J Clin 61 69-90

[3] Lopez-Casas PP(2014)Comprehensive molecular profiling of lung adenocarcinoma Nature 511 543-550

[4] Jones S(2010)High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer J Thorac Oncol 5 305-313

[5] Katz A(2006)Somatic mutations lead to an oncogenic deletion of met in lung cancer Cancer Res 66 283-289

[6] Kann LM(2007)MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039-1043

[7] Lopez-Rios F(2013)Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives J Clin Oncol 31 1997-2003

[8] Sarno F(2008)Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer J Thorac Oncol 3 477-482

[9] Al-Shahrour F(2011)Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification J Thorac Oncol 6 942-946

[10] Vasquez D(2014)Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement Lung Cancer 83 109-111

[1] Garralda E(2014)Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment Clin Cancer Res 20 2476-2484

[2] Paz K(2011)Global cancer statistics CA Cancer J Clin 61 69-90

[3] Lopez-Casas PP(2014)Comprehensive molecular profiling of lung adenocarcinoma Nature 511 543-550

[4] Jones S(2010)High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer J Thorac Oncol 5 305-313

[5] Katz A(2006)Somatic mutations lead to an oncogenic deletion of met in lung cancer Cancer Res 66 283-289

[6] Kann LM(2007)MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039-1043

[7] Lopez-Rios F(2013)Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives J Clin Oncol 31 1997-2003

[8] Sarno F(2008)Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer J Thorac Oncol 3 477-482

[9] Al-Shahrour F(2011)Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification J Thorac Oncol 6 942-946

[10] Vasquez D(2014)Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement Lung Cancer 83 109-111